Nasal Swab Test Spots Early Alzheimer’s Signals, Study Finds

Alzheimer’s disease, a devastating neurodegenerative condition affecting millions globally, is notoriously difficult to detect in its earliest stages – precisely when new treatments are most likely to be effective. However, a groundbreaking new study from Duke Health researchers reveals a potential game-changer: a quick, outpatient nasal swab capable of identifying biological changes linked to Alzheimer’s even before the onset of cognitive or memory problems.

How the Nasal Swab Test Works

Published March 18, 2026, in Nature Communications, the study details a minimally invasive procedure utilizing a gentle swab placed high inside the nose to collect nerve and immune cells. Researchers then analyze these cells, focusing on gene activity as a marker of changes occurring within the brain. The procedure itself takes only a few minutes to complete, involving a numbing spray followed by the collection of cells from the upper nasal cavity, where smell-detecting nerve cells reside.

Identifying Patterns of Alzheimer’s Disease

By analyzing the collected cells, researchers identified distinct patterns that effectively differentiated individuals with early or diagnosed Alzheimer’s from those without the disease. The study, which involved 22 participants, measured the activity of thousands of genes across hundreds of thousands of individual cells, generating millions of data points. A combined gene score from the nasal tissue correctly separated early and clinical Alzheimer’s from healthy controls approximately 81% of the time. This suggests the nasal swab can detect subtle shifts in nerve and immune cells, even in individuals who haven’t yet exhibited symptoms but show lab-based signs of the disease.

The Significance of Early Detection

“We want to be able to confirm Alzheimer’s particularly early, before damage has a chance to build up in the brain,” explains Dr. Bradley J. Goldstein, corresponding author and professor at Duke University School of Medicine. “If we can diagnose people early enough, we might be able to start therapies that prevent them from ever developing clinical Alzheimer’s.”

Current Alzheimer’s diagnostic methods, such as blood tests, often detect markers that appear later in the disease process. This new nasal swab approach offers a potentially earlier and more direct assessment of disease-related changes by capturing living nerve and immune activity. As Vincent M. D’Anniballe, the study’s first author, notes, “Much of what we know about Alzheimer’s comes from autopsy tissue. Now we can study living neural tissue, opening new possibilities for diagnosis and treatment.”

Future Directions and Research Expansion

The Duke team, in collaboration with the Duke & UNC Alzheimer’s Disease Research Center, is currently expanding the research to include larger participant groups. They are also investigating whether the nasal swab can be used to monitor the effectiveness of Alzheimer’s treatments over time. Duke University has filed a U.S. Patent related to this innovative diagnostic approach. This research was funded by the National Institutes of Health.

Personal Impact of the Research

Mary Umstead, a voluntary participant in the study, shared her motivation for joining the research, stating her desire to honor her late sister, Mariah, who passed away from young-onset Alzheimer’s. “I would never want any family to have to go through that kind of loss that we went through with Mariah,” she said. “I would never want any patient to go through what she went through either.”